Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy.

Océane Landon-CardinalYves AllenbachAntoine SoulagesAude RigoletBaptiste HervierNicolas ChamptiauxQuentin MonzaniGuilhem SoleOlivier Benveniste

Published in: The Journal of rheumatology (2018)

One-third of patients with refractory anti-HMGCR had improved strength or other evidence of improved disease activity following RTX treatment.

Keyphrases